Thus , we aimed to assess correlations of VEGFR-@ and CXCR@ expression levels with clinical outcome in a randomized phase III study of patients with oxaliplatin/leucovorin/@-FU ( FLO ) versus cisplatin/leucovorin/@-FU ( FLP ) .